Medical diagnostics firm Biomerica's Q2 revenue falls amid product transition

Biomerica

14/01/2026 22:30

Overview

Medical diagnostics firm's Q2 revenue fell yr/yr due to absence of large distributor orders

Net loss for Q2 widened to $1.32 mln from $0.95 mln last year

Company entered marketing agreement with Henry Schein for inFoods IBS test

Outlook

Biomerica sees incremental revenue from inFoods IBS and new partnerships driving margin expansion

Company expects Medicare payment rate to expand patient access to inFoods IBS

Biomerica plans to leverage regulatory approval in Egypt for international expansion

Result Drivers

PRODUCT TRANSITION - Biomerica is shifting focus from lower-margin products to higher-margin diagnostic-guided therapy products, impacting current revenue

MENA REGION ORDERS - Revenue decline attributed to absence of large initial distributor orders in MENA region

COST MANAGEMENT - Operating expenses decreased by 4% year-to-date due to cost discipline and operational efficiency

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
$1.21 mln
Q2 Net Income
-$1.32 mln
Q2 Gross Margin
4.00%
Q2 Operating Expenses
$1.42 mln
Q2 Operating Income
-$1.37 mln


Press Release: ID:nGNX2y46Vp

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)